Publications

ADORED Trial Results to be Presented at AAAAI on February 28th 2026

Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study

Siolta Therapeutics is Awarded a Phase I SBIR to Develop an LBP for Prevention of Necrotizing Enterocolitis

Siolta Therapeutics is Awarded a $3M Phase II SBIR to Advance Innovative Anaerobic Biotherapeutic Manufacturing

ADORED Study Update: Final Trial Participant Completes the ADORED Study. Day 672 Readout is Expected in Q1 2026.

Siolta Therapeutics is Awarded a $1.8M Phase II SBIR to Develop a Live Biotherapeutic for Recurrent Bacterial Vaginosis